Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) was the target of a large decline in short interest in the month of September. As of September 15th, there was short interest totalling 15,280,000 shares, a decline of 5.5% from the August 31st total of 16,170,000 shares. Based on an average daily trading volume, of 1,590,000 shares, the short-interest ratio is presently 9.6 days.
Apellis Pharmaceuticals Price Performance
APLS stock opened at $29.47 on Monday. The company has a 50 day simple moving average of $37.01 and a 200 day simple moving average of $42.49. The stock has a market cap of $3.58 billion, a price-to-earnings ratio of -8.52 and a beta of 0.88. Apellis Pharmaceuticals has a 1 year low of $29.28 and a 1 year high of $73.80. The company has a debt-to-equity ratio of 1.73, a current ratio of 5.08 and a quick ratio of 4.18.
Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) last released its quarterly earnings data on Thursday, August 1st. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.03. The business had revenue of $199.70 million during the quarter, compared to analysts’ expectations of $190.89 million. Apellis Pharmaceuticals had a negative net margin of 52.99% and a negative return on equity of 138.32%. The firm’s quarterly revenue was up 110.2% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.02) EPS. Research analysts anticipate that Apellis Pharmaceuticals will post -1.34 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Check Out Our Latest Stock Report on Apellis Pharmaceuticals
Insider Buying and Selling
In related news, Director A. Sinclair Dunlop sold 37,000 shares of Apellis Pharmaceuticals stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $36.23, for a total transaction of $1,340,510.00. Following the completion of the sale, the director now owns 100,000 shares of the company’s stock, valued at approximately $3,623,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 6.80% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Apellis Pharmaceuticals
A number of institutional investors have recently added to or reduced their stakes in the stock. Teachers Retirement System of The State of Kentucky acquired a new position in Apellis Pharmaceuticals in the 2nd quarter valued at approximately $725,000. Algert Global LLC increased its position in Apellis Pharmaceuticals by 137.8% in the 2nd quarter. Algert Global LLC now owns 123,628 shares of the company’s stock valued at $4,742,000 after acquiring an additional 71,650 shares during the period. AQR Capital Management LLC increased its position in Apellis Pharmaceuticals by 337.3% in the 2nd quarter. AQR Capital Management LLC now owns 246,880 shares of the company’s stock valued at $9,177,000 after acquiring an additional 190,420 shares during the period. Toronto Dominion Bank increased its position in Apellis Pharmaceuticals by 146.0% in the 2nd quarter. Toronto Dominion Bank now owns 24,600 shares of the company’s stock valued at $944,000 after acquiring an additional 14,601 shares during the period. Finally, Squarepoint Ops LLC acquired a new position in Apellis Pharmaceuticals in the 2nd quarter valued at approximately $2,350,000. 96.29% of the stock is currently owned by institutional investors and hedge funds.
Apellis Pharmaceuticals Company Profile
Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).
Further Reading
- Five stocks we like better than Apellis Pharmaceuticals
- Top Biotech Stocks: Exploring Innovation Opportunities
- 3 Multi-Bagger Stocks to Buy Now for Explosive Growth
- How Technical Indicators Can Help You Find Oversold StocksĀ
- Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Citi Analysts Turn More Bullish on Walmart Stock: Time to Buy?
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.